This move is archived. Current quotes and coverage live on the stock page.
Get BCT alerts:
Briacell Therapeutics Corp is facing challenges as its stock takes a hit amid ongoing regulatory uncertainties.
In the latest trading session, Briacell Therapeutics Corp (BCT.TO) saw its stock price drop by 2.09%, closing at CA$4.21. This decline raises concerns among investors about the company's future, especially following its recent partnership announcement.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$51.42M
52W high
$20.40
52W low
$3.68
1W change
+17.26%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT · as of Sep 17, 2026
Wall Street analysts forecast BCT stock price to rise 238.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+238.4% Upside
Current Price
C$5.91
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
91.6%
Annualized
90-Day Vol
91.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$7.07
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.27 | C$4.57 – C$8.60 |
| 60 trading days | C$6.66 | C$4.26 – C$10.41 |
| 90 trading days | C$7.07 | C$4.09 – C$12.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Briacell's developments, particularly regarding the regulatory approval of its lead candidate, Bria-IMT. Any delays could further impact stock performance.
Briacell's Market Cap at CA$37.67 Million
Despite the recent downturn, Briacell Therapeutics has a market cap of CA$37.67 million, showing some investor confidence in its long-term potential.
Bull case
The partnership with Uneedle could improve the administration of Bria-IMT, potentially leading to a smoother path toward commercialization if they can clear regulatory hurdles.
Bear case
The stock's decline reflects investor worries about the uncertainties surrounding regulatory approvals and the readiness of Bria-IMT for the market, which could slow growth.
Recent Developments
Advertisement
Briacell recently announced a partnership with Uneedle to use microneedle technology for administering Bria-IMT in a pivotal Phase 3 study for metastatic breast cancer. While this development is promising, the success of this collaboration depends on overcoming regulatory challenges.
Market Reaction
The stock's 2.09% decline shows that investors are concerned about the timeline for regulatory approvals. With a market cap of CA$37.67 million, the market's reaction suggests many are cautious about potential delays in bringing Bria-IMT to market, which could affect the company's financial outlook.
Looking Ahead
Investors should closely monitor Briacell's progress with Bria-IMT and the implications of its partnership with Uneedle. Successfully navigating regulatory processes will be crucial for the company's future stock performance and overall viability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
